A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy: LATIFY
Advanced or Metastatic Non-Small Cell Lung Cancer
Ceralasertib, Durvalumab, Docetaxel
18 Years - n/a
Endpoint Classification: -
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Verified 01 Aug 2023 by AstraZeneca
No locations available
|Experimental: Group A: Ceralasertib plus durvalumab combination therapy|
Participants will be administered ceralasertib orally followed by durvalumab administered intravenously.
Participants will receive ceralasertib oral tablets.
Participants will receive durvalumab as an intravenous infusion.
|Active Comparator: Group B: Docetaxel monotherapy|
Participants will be administered docetaxel (standard of care) administered intravenously.
Participants will received docetaxel as an intravenous infusion.